Name :
Human TWEAKR Protein, ECD (Extracellular Domain), Fc-fusion, Biotinylated, Recombinant
Description :
TWEAKR (TNFrelated weak inducer of apoptosis receptor) s a single-pass, type I transmembrane glycoprotein in the TNF receptor superfamily (TNFRSF12). TWEAKR was originally identified as a fibroblast growth factorinducible immediateearly response gene termed Fn14 in mouse fibroblast cells. Human and mouse TWEAKR share 82% amino acid sequence identity. TWEAKR is detected in almost all tissues examined. It is highly expressed in heart, placenta and kidney with intermediate expression in lung, skeletal muscle and pancreas. TWEAKR is the smallest member of the TNFRSF and contains only one cysteinerich region in its extracellular region that mediates the interaction with its ligand TWEAK. TWEAKR binds TWEAK with high affinity to initiate a signal transduction cascade in cell type dependent manner. The ligation leads to a variety of cellular responses including apoptosis, cell proliferation, and angiogenesis. The cytoplasmic domain of TWEAKR contains one TRAF binding motif which bindsTRAF1, TRAF2, and TRAF3 to initiate signal transduction. TWAEKR is a weak inducer of apoptosis in some cell types. TWEAKR promotes angiogenesis and the proliferation of endothelial cells. It may also modulate cellular adhesion to matrix proteins. Elevated levels of TWEAKR were found in hepatocellular carcinoma specimens, in regenerating mouse liver and in injured rat arteries.
Gene Symbol :
TWEAKR; TNFRSF12A; CD266; FN14; TWEAK-R
NCBI Gene ID :
51330
Uniprot Entry :
Q9NP84
Construct Details :
The recombinant human TWEAKR-Fc fusion is expressed as a 281 amino acid protein consisting of Glu28- Pro80 region of TWEAKR (UniProt accession #Q9NP84) and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions (see the gel image above).
Source :
Human cells stably expressing human TWEAKR-Fc and growing in chemical-defined media with no animal components or antibiotics
Amino Acid Sequence: :
10 20 30 40 50 60 EQAPGTAPCS RGSSWSADLD KCMDCASCRA RPHSDFCLGC AAAPPAPFRL LWPSTGTHTC 70 80 90 100 110 120 PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN 130 140 150 160 170 180 AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 190 200 210 220 230 240 QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL 250 260 270 280 YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
M.W. :
Calculated molecular mass (kDa): 31.1; Estimated by SDS-PAGE under reducing condition (kDa): ~40
Calculated PI :
7.21
Calculated Extinction Coefficients :
(M-1 cm-1, at 280nm): 47160
Endotoxin Level :
>95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as “DTT: +”)
Formulation :
Supplied at 0.5 mg/ml in sterile PBSpH7.4 (carrier & preservative free). The purified recombinant protein was labeled with Biotin (3-5 Biotin per molecule) using the standard procedure.
Endotoxin Level :
<0.1 EU per 1 μg of purified recombinant protein determined by the LAL method
Biological Activity :
Binds to its ligand TWEAK/TNFSF12 and inhibits TWEAK-mediated signaling activities including TWEAK-induced apoptosis in HT-29 human colon cancer cells and proliferation of human umbilical vein endothelial cells (HUVECs).
Molecule Class :
1-Pass Type I Transmembrane
Gene Synonym :
<0.1 EU per 1 μg of purified recombinant protein determined by the LAL method
Gene Family :
TNFRSF12A; CD266; FN14; TWEAK-R
Research Area :
Immunology
Pathway/Disease :
TWEAK Signaling Pathway
Species :
Human
CD Antigen :
CD266
References :
1. J. Biol. Chem. 274:8455 (1999). 2. J. Biol. Chem. 274:33166 (1999). 3. Am J. Pathol. 156:1253 (2000). 4. Immunity 15:837 (2001). 5. J. Immunol. 168:734 (2002). 6. Protein Sci. 18:650 (2009).
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
TSLP Protein
FGF-8f Protein
Popular categories:
Aminopeptidase N/CD13
UEV-1